In January, China’s pharmaceutical exports reached US$5.77 billion, a year-on-year increase of 13.9%, of which Western medicine exports stood at US$3.52 billion, up 19.5% year-on-year, medical device exports reached US$1.91 billion, up 7.3% year-on-year, and Chinese medicines exports stood at US$340 million, a year-on-year increase of 0.5%.
In addition to holiday factors, the major factor in the rapid growth of exports in January was the recovery of the Western medicine export market. The export prices of APIs continued to increase. The increase in the overall export volume of APIs was close to US$500 million, accounting for 70% of the total increase in pharmaceutical exports. The prices of bulk APIs such as VE, tetracycline, and 6APA continued to rise, and VB12 reached US$900/kg, a 35.1% increase from the previous month. In the export market, the major markets recovered significantly. In the United States, the EU’s growth rates reached 40.1% and 22.6%, respectively. Exports to India increased by 14.7%.
The highlight of the export in January was the US$330 million in exports of pharmaceutical preparations, a significant increase of 29.4%. The increase was concentrated in local pharmaceutical companies, Qilu Pharmaceutical, Hua Pharmaceutical, Tiandao Pharmaceutical, Guilin Nanyao, and Shiyao Group achieved substantial growth, including Tiandao. The export of medicine and Guilin South medicine increased by more than 200%.
Click on the image below to register for the exhibition!
